COLLEGEVILLE, Pa., October 15, 2007 /PRNewswire-FirstCall/ --
Wyeth Pharmaceuticals, a division of Wyeth , reported that new
study data presented today at the 63rd Annual Meeting of the
American Society for Reproductive Medicine (ASRM) showed that women
who received 100 mg/day or 150 mg/day of desvenlafaxine, a
serotonin and norepinephrine reuptake inhibitor (SNRI), experienced
a significant reduction in moderate to severe vasomotor symptoms
(VMS) (hot flashes and night sweats) associated with menopause over
those taking placebo. This significant reduction was seen as early
as week one.

The common adverse drug reactions (greater than or equal to five
percent of either desvenlafaxine group) in this study were
asthenia, hypertension, anorexia (loss of appetite), constipation,
diarrhea, dry mouth, nausea, dizziness, insomnia, somnolence and
mydriasis.

"There are more than 10 million menopausal women who experience
moderate to severe hot flashes and night sweats. Only a small
percentage of menopausal women use FDA-approved treatments, all of
which are hormone-based," says Ginger Constantine, M.D., Vice
President, Women's Health Care, Wyeth Pharmaceuticals. "Wyeth is
committed to continuing to develop desvenlafaxine as a potential
non-hormonal treatment option for women with moderate to severe
vasomotor symptoms associated with menopause."

In July 2007, Wyeth received an approvable letter from the FDA
for desvenlafaxine in the treatment of moderate to severe vasomotor
symptoms associated with menopause. Wyeth is working with the FDA
to address several items in the letter and to gain agreement on the
design of one additional safety study. The efficacy and safety data
for desvenlafaxine presented at the meeting represents only a
portion of the totality of data that the Company has submitted to
the FDA.

"Additional treatment options are important for the millions of
U.S. women experiencing hot flashes and night sweats associated
with menopause," says David F. Archer, lead investigator of the
12-week study and professor in the Department of Obstetrics and
Gynecology, Eastern Virginia Medical School, Clinical Research
Center, Norfolk, Virginia. "Vasomotor symptoms can be quite
disruptive for women in performing their daily activities. The
study findings presented show that desvenlafaxine significantly
reduced the number of hot flashes in postmenopausal women, and
thus, if approved, may be an important treatment option."

About the Posters

Below are summaries of three separate analyses of the 12-week,
multicenter, randomized, double-blind, placebo-controlled study.
Postmenopausal women (N=458) with 50 or more moderate to severe hot
flashes per week received either desvenlafaxine 100 mg/day, 150
mg/day or placebo. In addition, also presented was a secondary
analysis of a previously presented 52-week study with
desvenlafaxine.

The analysis of the 12-week trial showed that desvenlafaxine 100
mg significantly reduced the frequency of moderate to severe hot
flashes by 65 percent from baseline to the end of the trial,
compared to a 51 percent reduction for placebo. This reduction in
frequency of hot flashes with desvenlafaxine 100 mg was seen
beginning at week one. The severity of hot flashes also reduced
significantly at all time points compared to placebo among
postmenopausal women who received desvenlafaxine.

Poster 421: Farmer M., et al. Safety and Tolerability of
Desvenlafaxine Succinate in a Double-Blind, Placebo-Controlled
Trial for the Relief of Vasomotor Symptoms Associated With
Menopause

The safety analysis of the 12-week study showed that
desvenlafaxine was generally well tolerated when patients started
with a lower dose (50 mg/day) and then titrated to 100 mg/day.
Nausea was reported by 25 percent of postmenopausal women who
received either dose of desvenlafaxine, compared to seven percent
in those who received placebo. Overall, adverse events led to
discontinuation from the study in 11 percent in the desvenlafaxine
dose groups, compared to seven percent of those receiving
placebo.

There were few clinically important laboratory and vital sign
changes, with no significant differences among treatment groups.
Discontinuation symptoms have been generally observed with SNRIs
and selective serotonin reuptake inhibitors (SSRIs). In this study,
discontinuation symptoms were reported by 51 percent of women
taking desvenlafaxine vs. 38 percent with women taking placebo.

Results from this secondary analysis of the 12-week study showed
that desvenlafaxine 100 mg or 150 mg improved total mood
disturbance score as measured by the Profile of Mood States (POMS),
and climacteric symptoms as measured by the Greene Climacteric
Scale (GCS), in postmenopausal women with moderate to severe
vasomotor symptoms. Mood and climacteric symptoms were assessed by
POMS and GCS, respectively, at baseline and weeks 4 and 12.

About Desvenlafaxine

Wyeth Pharmaceuticals is committed to improving the care of
patients and understanding the clinical and safety information
about its products. The clinical development program for
desvenlafaxine involves thousands of subjects and represents a
continued exploration of the molecule's potential utility in
multiple conditions.

Important Information

Antidepressants, including SSRIs and SNRIs, increased the risk
compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents and young adults in short-term studies of
Major Depressive Disorder (MDD) and other psychiatric disorders.
Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all
ages who are started on antidepressant therapy should be monitored
appropriately and observed closely for clinical worsening,
suicidality, or unusual changes in behavior. Families and
caregivers should be advised of the need for close observation and
communication with the prescriber.

Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader
in the discovery, development, manufacturing and marketing of
pharmaceuticals, vaccines, biotechnology products and
non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical
facts are forward-looking statements based on current expectations
of future events and are subject to risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include the inherent uncertainty of the timing and
success of, and expense associated with, research, development,
regulatory approval and commercialization of our products and
pipeline products (including desvenlafaxine); government
cost-containment initiatives; restrictions on third-party payments
for our products; substantial competition in our industry,
including from branded and generic products; data generated on our
products; the importance of strong performance from our principal
products and our anticipated new product introductions; the highly
regulated nature of our business; product liability, intellectual
property and other litigation risks and environmental liabilities;
uncertainty regarding our intellectual property rights and those of
others; difficulties associated with, and regulatory compliance
with respect to, manufacturing of our products; risks associated
with our strategic relationships; economic conditions including
interest and currency exchange rate fluctuations; changes in
generally accepted accounting principles; trade buying patterns;
the impact of legislation and regulatory compliance; risks and
uncertainties associated with global operations and sales; and
other risks and uncertainties, including those detailed from time
to time in our periodic reports filed with the Securities and
Exchange Commission, including our current reports on Form 8-K,
quarterly reports on Form 10-Q and annual report on Form 10-K,
particularly the discussion under the caption "Item 1A, Risk
Factors." The forward-looking statements in this press release are
qualified by these risk factors. We assume no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.